Does RISANKIZUMAB-RZAA Cause Interstitial lung disease? 45 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 45 reports of Interstitial lung disease have been filed in association with RISANKIZUMAB-RZAA. This represents 0.1% of all adverse event reports for RISANKIZUMAB-RZAA.
45
Reports of Interstitial lung disease with RISANKIZUMAB-RZAA
0.1%
of all RISANKIZUMAB-RZAA reports
2
Deaths
9
Hospitalizations
How Dangerous Is Interstitial lung disease From RISANKIZUMAB-RZAA?
Of the 45 reports, 2 (4.4%) resulted in death, 9 (20.0%) required hospitalization, and 3 (6.7%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RISANKIZUMAB-RZAA. However, 45 reports have been filed with the FAERS database.
What Other Side Effects Does RISANKIZUMAB-RZAA Cause?
Psoriasis (6,896)
Drug ineffective (2,885)
Pain (2,584)
Fatigue (2,483)
Arthralgia (2,419)
Pruritus (2,311)
Covid-19 (2,145)
Death (1,700)
Fall (1,666)
Surgery (1,662)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which RISANKIZUMAB-RZAA Alternatives Have Lower Interstitial lung disease Risk?
RISANKIZUMAB-RZAA vs RISDIPLAM
RISANKIZUMAB-RZAA vs RISEDRONATE
RISANKIZUMAB-RZAA vs RISEDRONIC ACID
RISANKIZUMAB-RZAA vs RISPERDAL
RISANKIZUMAB-RZAA vs RISPERDAL CONSTA